Target Price Review & Stock Update on Ascendis Pharma A/S (NASDAQ:ASND)

Equity research analysts have provided views on where they believe the stock will be trading in the future. According to Thomson Reuters, analysts are projecting a consensus target price of $29.670 on company shares. Sell-side analysts tap into their vast knowledge of the company to help gauge future stock movement. Because of the various techniques used, analysts may come up with very different stock target estimates. 

Wall Street analysts have the ability to use various metrics to help calculate target projections. A commonly used metric is a company’s P/E Ratio. This calculation stems from dividing the current share price by the projected earnings per share. At the time of this writing, Ascendis Pharma A/S – American has a price to earnings ratio of N/A. Investors may also evaluate a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may indicate that the company is overvalued. A PEG Ratio near one may be seen as fair value. The stock presently has a PEG Ratio of -0.270.

Taking a brief view of stock performance, we see that company shares are currently trading $0.778 off the 50-day moving average of $19.727 and $3.840 off of the 200-day moving average of $16.665. The stock has been recently recorded -5.897% off of the 52-week high of 21.790 and +72.022% away from the 52-week low of 11.920. Tracking the stock price relative to moving averages and highs and lows for the year may help evaluate the future value of the stock.